Efficacy of Natalizumab in a French Cohort of Multiple Sclerosis Patients

被引：0
|
作者：
Outteryck, Olivier
Ongagna, Jean-Claude
Zephir, Helene
Fleury, M. -C.
Lacour, Arnaud
Blanc, Frederic
Vermersch, Patrick
de Seze, Jerome
机构：
来源：
NEUROLOGY | 2010年 / 74卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A550 / A551
页数：2
相关论文
共 50 条
  • [41] The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study
    Fernandez, Oscar
    Papais Alvarenga, Marcos
    Guerrero, Miguel
    Leon, Antonio
    Alonso, Ana
    Carlos Lopez-Madrona, Jose
    Leyva, Laura
    Oliver, Begona
    de Ramon, Enrique
    Luque, Gloria
    Fernandez, Victoria
    MULTIPLE SCLEROSIS, 2011, 17 (02): : 192 - 197
  • [42] Efficacy and Safety of Natalizumab in Multiple Sclerosis: Interim Observational Program Results from an Australian Cohort.
    Butzkueven, H.
    Barnett, M.
    Broadley, S.
    Hodgkinson, S.
    King, J.
    Kneebone, C.
    Slee, M.
    Lechner-Scott, J.
    Kermode, A.
    Shuey, N.
    Macdonell, R.
    Chen, Y.
    Naidoo, K.
    Koendgen, H.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (03) : 419 - 420
  • [43] Natalizumab in multiple sclerosis
    Rajda Cecilia
    Bencsik Krisztina
    Vecsei Laszlo
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2008, 61 (5-6): : 204 - 208
  • [44] Natalizumab for multiple sclerosis
    Ransohoff, Richard M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (25): : 2622 - 2629
  • [45] Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis
    Signoriello, E.
    Lanzillo, R.
    Morra, V. Brescia
    Di Iorio, G.
    Fratta, M.
    Carotenuto, A.
    Lus, G.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (07) : 921 - 925
  • [46] Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab
    Patti, Francesco
    Pappalardo, Angelo
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2009, 1 : 45 - 51
  • [47] Efficacy, safety and tolerability of natalizumab in Turkish multiple sclerosis patients with high disease activity: a hospital-based cohort at a university faculty of medicine, multiple sclerosis unit, Istanbul
    Eraksoy, M.
    Mutlu, M.
    Akman-Demir, G.
    JOURNAL OF NEUROLOGY, 2009, 256 : S240 - S240
  • [48] Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients
    Sangalli, Francesca
    Moiola, Lucia
    Ferre, Laura
    Radaelli, Marta
    Barcella, Valeria
    Rodegher, Mariaemma
    Colombo, Bruno
    Boneschi, Filippo Martinelli
    Martinelli, Vittorio
    Comi, Giancarlo
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2014, 3 (04) : 520 - 526
  • [49] Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients
    Heesen, Christoph
    Kleiter, Ingo
    Meuth, Sven G.
    Kraemer, Julia
    Kasper, Juergen
    Koepke, Sascha
    Gaissmaier, Wolfgang
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 376 : 181 - 190
  • [50] The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study
    Mazdeh, Mehrdokht
    Hosseini, Shno
    Taheri, Mohammad
    Ghafouri-Fard, Soudeh
    CLINICAL AND TRANSLATIONAL MEDICINE, 2018, 7
12345